Diagnostic modified-nucleoside detection assay

Abstract

The present invention relates to an assay for the detection of modified nucleoside levels in a patient. Detection of the modified nucleoside levels in a patient having a disease such as cancer allows for the progression of the disease to be followed and therapeutic regimens to be altered. Such an assay is particularly useful in following the response of cancer patients to chemotherapeutic treatment.

We claim:  
     
         1 . A method for determining the effectiveness of a treatment regimen for treating a condition such as cancer comprising determining the concentration of a modified nucleoside in a bodily fluid of a patient suspected of having cancer wherein an increased or decreased level of modified nucleoside relative to the level of modified nucleoside detected in the bodily fluid isolated prior to treatment indicates the effectiveness of the treatment regimen.  
     
     
         2 . A method of    claim 1    wherein said modified nucleoside is selected from the group consisting of psueouridine (ψ), 7-methylinosine (m 7 I), and 1-methyladenosine (m 1 A).  
     
     
         3 . A method of    claim 1    wherein psueouridine (ψ), 7-methylinosine (m 7 I), and 1-methyladenosine (m 1 A) are detected.  
     
     
         4 . A method of    claim 1    wherein said condition is brain cancer.  
     
     
         5 . A method of    claim 1    wherein said condition is glioma or meningioma.  
     
     
         6 . A method for determining the effectiveness of a treatment regimen for treating a condition such as cancer comprising: 
 a) adding to a bodily fluid of a patient to be treated a first antibody having immunological reactivity to a modified nucleoside comprising a label;    b) contacting the bodily fluid of step (a) with a solid surface to which a second antibody specific to a modified nucleoside is bound under conditions suitable to the formation of a complex of said modified nucleoside with said labeled antibody and the antibody bound to the solid surface; and    c) detecting the labeled antibody;    wherein detection of the labeled antibody indicates the presence of a modified nucleoside within the biological fluid.    
     
     
         7 . A method of    claim 1    wherein said modified nucleoside is selected from the group consisting of psueouridine (ψ), 7-methylinosine (m 7 I), and 1-methyladenosine (m 1 A).  
     
     
         8 . A method of    claim 1    wherein psueouridine (ψ), 7-methylinosine (m 7 I), and 1-methyladenosine (m 1 A) are detected.  
     
     
         9 . A method of    claim 1    wherein said condition is brain cancer.  
     
     
         10 . A method of    claim 1    wherein said condition is glioma or meningioma.  
     
     
         11 . A method of    claim 5    wherein said solid surface support is a dipstick.  
     
     
         12 . A method for diagnosing cancer comprising determining the concentration of a modified nucleoside in a bodily fluid of a patient suspected of having cancer wherein an increased or decreased level of modified nucleoside relative to the level of modified nucleoside detected in the bodily fluid of a patient that does not have cancer indicates the presence of cancer.  
     
     
         13 . A method of    claim 12    wherein said modified nucleoside is selected from the group consisting of psueouridine (ψ), 7-methylinosine (m 7 I), and 1-methyladenosine (m 1 A).  
     
     
         14 . A method of    claim 12    wherein psueouridine (ψ), 7-methylinosine (m 7 I), and 1-methyladenosine (m 1 A) are detected.  
     
     
         15 . A method of    claim 12    wherein said condition is brain cancer.  
     
     
         16 . A method of    claim 12    wherein said condition is glioma or meningioma.  
     
     
         17 . A method for diagnosing cancer comprising: 
 a) adding to a bodily fluid of a patient to be treated a first antibody having immunological reactivity to a modified nucleoside comprising a label;    b) contacting the bodily fluid of step (a) with a solid surface to which a second antibody specific to a modified nucleoside is bound under conditions suitable to the formation of a complex of said modified nucleoside with said labeled antibody and the antibody bound to the solid surface; and    c) detecting the labeled antibody;    wherein detection of the labeled antibody indicates the presence of cancer.    
     
     
         18 . A method of    claim 17    wherein said modified nucleoside is selected from the group consisting of psueouridine (ψ), 7-methylinosine (m 7 I), and 1-methyladenosine (m 1 A).  
     
     
         19 . A method of    claim 17    wherein said condition is a brain cancer.  
     
     
         20 . A method of    claim 17    wherein said solid surface support is a dipstick.